Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial

磷酸西他列汀 医学 甘精胰岛素 二甲双胍 耐受性 2型糖尿病 内科学 胰岛素 糖尿病 二肽基肽酶-4抑制剂 2型糖尿病 低血糖 内分泌学 不利影响
作者
Pablo Aschner,Juliana C.N. Chan,David R. Owens,Sylvie Picard,Edward Wang,Marie-Paule Dain,Valérie Pilorget,Akram Echtay,Vivian Fonseca
出处
期刊:The Lancet [Elsevier BV]
卷期号:379 (9833): 2262-2269 被引量:99
标识
DOI:10.1016/s0140-6736(12)60439-5
摘要

Background In people with type 2 diabetes, a dipeptidyl peptidase-4 (DPP-4) inhibitor is one choice as second-line treatment after metformin, with basal insulin recommended as an alternative. We aimed to compare the efficacy, tolerability, and safety of insulin glargine and sitagliptin, a DPP-4 inhibitor, in patients whose disease was uncontrolled with metformin. Methods In this comparative, parallel, randomised, open-label trial, metformin-treated people aged 35–70 years with glycated haemoglobin A1c (HbA1c) of 7–11%, diagnosis of type 2 diabetes for at least 6 months, and body-mass index of 25–45 kg/m2 were recruited from 17 countries. Participants were randomly assigned (1:1) to 24-week treatment with insulin glargine (titrated from an initial subcutaneous dose of 0·2 units per kg bodyweight to attain fasting plasma glucose of 4·0–5·5 mmol/L) or sitagliptin (oral dose of 100 mg daily). Randomisation (via a central interactive voice response system) was by random sequence generation and was stratified by centre. Patients and investigators were not masked to treatment assignment. The primary outcome was change in HbA1c from baseline to study end. Efficacy analysis included all randomly assigned participants who had received at least one dose of study drug and had at least one on-treatment assessment of any primary or secondary efficacy variable. This trial is registered at ClinicalTrials.gov, NCT00751114. Findings 732 people were screened and 515 were randomly assigned to insulin glargine (n=250) or sitagliptin (n=265). At study end, adjusted mean reduction in HbA1c was greater for patients on insulin glargine (n=227; −1·72%, SE 0·06) than for those on sitagliptin (n=253; −1·13%, SE 0·06) with a mean difference of −0·59% (95% CI −0·77 to −0·42, p<0·0001). The estimated rate of all symptomatic hypoglycaemic episodes was greater with insulin glargine than with sitagliptin (4·21 [SE 0·54] vs 0·50 [SE 0·09] events per patient-year; p<0·0001). Severe hypoglycaemia occurred in only three (1%) patients on insulin glargine and one (<1%) on sitagliptin. 15 (6%) of patients on insulin glargine versus eight (3%) on sitagliptin had at least one serious treatment-emergent adverse event. Interpretation Our results support the option of addition of basal insulin in patients with type 2 diabetes inadequately controlled by metformin. Long-term benefits might be expected from the achievement of optimum glycaemic control early in the course of the disease. Funding Sanofi.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
1秒前
水木青年关注了科研通微信公众号
1秒前
hehehaha发布了新的文献求助30
2秒前
loser发布了新的文献求助10
2秒前
2秒前
4秒前
向日葵发布了新的文献求助10
4秒前
1111完成签到,获得积分10
4秒前
小甲鱼发布了新的文献求助10
5秒前
9979发布了新的文献求助10
5秒前
LVZHIPENG发布了新的文献求助10
5秒前
科研通AI6.4的应助被彤彤采纳,获得10
5秒前
6秒前
初初初啊发布了新的文献求助10
6秒前
kun发布了新的文献求助100
7秒前
7秒前
KD完成签到,获得积分10
7秒前
7秒前
8秒前
9秒前
麦穗大旋风完成签到,获得积分10
9秒前
星辰大海的应助被zyr采纳,获得10
10秒前
在水一方的应助被科研通管家采纳,获得10
10秒前
今后的应助被科研通管家采纳,获得10
10秒前
在水一方的应助被科研通管家采纳,获得10
11秒前
庞扬完成签到,获得积分20
11秒前
小蘑菇的应助被科研通管家采纳,获得10
11秒前
研友_VZG7GZ的应助被科研通管家采纳,获得10
11秒前
ding的应助被科研通管家采纳,获得10
11秒前
dapang_han发布了新的文献求助10
11秒前
11秒前
云墨完成签到,获得积分20
11秒前
ding的应助被科研通管家采纳,获得10
11秒前
link发布了新的文献求助10
11秒前
11秒前
思源的应助被科研通管家采纳,获得10
11秒前
Xiaohuyan发布了新的文献求助10
12秒前
天天快乐的应助被科研通管家采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165074
求助须知:如何正确求助?哪些是违规求助? 9558738
关于积分的说明 21747291
捐赠科研通 7755624
什么是DOI,文献DOI怎么找? 3428780
关于科研通互助平台的介绍 2553162
邀请新用户注册赠送积分活动 2473361